恒瑞医药: 江苏恒瑞医药股份有限公司章程（草案 2025年4月）

General Provisions - The company aims to protect the legal rights of shareholders, employees, and creditors while regulating its organization and behavior according to relevant laws and regulations [1][2] - Jiangsu Hengrui Pharmaceuticals Co., Ltd. was established as a joint-stock company approved by the Jiangsu Provincial Government in 1997 and listed on the Shanghai Stock Exchange in 2000 [1][2] Business Objectives and Scope - The company's business objective is to focus on a primary industry while diversifying operations to optimize asset allocation and enhance operational efficiency, particularly in the production of anti-tumor and anesthetic drugs [3][4] - The registered business scope includes the manufacturing of various pharmaceutical forms, including tablets, injections, and biological products, as well as the research and development of medical devices [4] Shares - The company issues shares in the form of stocks, with a par value of RMB 1 per share, and has a total approved issuance of 132.85 million shares [6][18] - The company’s shares are categorized into A shares and H shares, with specific regulations governing their issuance and transfer [6][18] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company decisions, and they are obligated to comply with laws and the company’s articles of association [13][38] - Shareholders holding more than 5% of voting shares must report any pledges of their shares to the company [17] Shareholder Meetings - The company holds annual and extraordinary shareholder meetings, with specific procedures for convening and conducting these meetings [19][41] - Shareholders can propose agenda items for meetings, and the company must notify shareholders of meeting details in advance [53][56] Legal Compliance - The company must adhere to legal requirements regarding shareholder meetings, including the verification of shareholder identities and the legality of meeting procedures [66][68] - Legal opinions will be sought to ensure compliance with laws during shareholder meetings [46]